Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on UTHR stock, giving a Buy rating on June 10.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Roanna Ruiz has given her Buy rating due to a combination of factors that highlight United Therapeutics’ strategic positioning and innovative advancements. One of the key reasons is the company’s recent milestone in treating the first patient with miroliverELAP, a bioengineered liver support system. This development is significant as it marks the first human clinical trial of a manufactured organ alternative, showcasing United Therapeutics’ pioneering role in organ manufacturing.
Additionally, the unique clinical and regulatory positioning of miroliverELAP, being an external device, may simplify regulatory processes and facilitate gradual adoption similar to dialysis. This strategic move could enhance United Therapeutics’ credibility in the liver platform space. Furthermore, the company’s diversified pipeline, including xenotransplantation and regenerative medicine, strengthens its market position amid uncertainties in other areas, such as the TETON readouts. These factors collectively reinforce the Buy rating as they underscore United Therapeutics’ potential for long-term growth and innovation.
In another report released on June 10, Jefferies also maintained a Buy rating on the stock with a $432.00 price target.
Based on the recent corporate insider activity of 188 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year.